Table 1 Results of safety and efficacy test
Groups | A | B | C | D | ||
|---|---|---|---|---|---|---|
Virus tested | B-gD&gCS | Bartha K61 | / | / | ||
Dosage | 1 × 106 TCID50 | PBS | / | |||
Inoculation route | Intramuscularly | |||||
ELISA antibodies against PRV gB or gE | B.V. | gB+ | 0a/5b | 0/5 | 0/5 | 0/5 |
gE+ | 0/5 | 0/5 | 0/5 | 0/5 | ||
7d P.V. | gB+ | 5/5 | 5/5 | 0/5 | 0/5 | |
gE+ | 0/5 | 0/5 | 0/5 | 0/5 | ||
14 d P.C. | gB+ | 5/5 | 5/5 | 2/5 | 0/5 | |
gE+ | 5/5 | 5/5 | 2/5 | 0/5 | ||
Clinical signs P.V. | 0/5 | 0/5 | 0/5 | 0/5 | ||
Fever frequency (≥40.5 °C) P.V. | 0/5 | 0/5 | 0/5 | 0/5 | ||
Virus shedding P.V. | 0/5 | 0/5 | / | / | ||
Fever frequency (≥40.5 °C) P.C. | 0/5 | 0/5 | 5/5 | 0/5 | ||
Clinical signs P.C. | Morbidity | 0/5 | 0/5 | 5/5 | 0/5 | |
Duration (days) | / | / | 4~12 | / | ||
Mortality | 0/5 | 0/5 | 3/5 | 0/5 | ||
Virus shedding P.C. | Frequency | 3/5 | 5/5 | 5/5 | 0/5 | |
Titer (TCID50/g) | 102.49~106.19 | 101.30~109.82 | 101.30~108.83 | / | ||
Duration (days) | 1~8 | 4~10 | 3~10 | / | ||
Lung lesions P.C. | 0/5 | 0/5 | 5/5 | 0/5 | ||